Bedoradrine - Kissei Pharmaceutical/MediciNova

Drug Profile

Bedoradrine - Kissei Pharmaceutical/MediciNova

Alternative Names: Bedoradrine sulfate; KUR-1246; MLN-221; MN-221

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; MediciNova
  • Class Acetamides; Antiasthmatics; Ethanolamines; Naphthalenes; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute asthma

Highest Development Phases

  • Phase II Acute asthma; Preterm labour
  • Phase I Chronic obstructive pulmonary disease
  • No development reported Status asthmaticus

Most Recent Events

  • 09 Feb 2018 Phase-II clinical trials in Preterm labour in USA (IV) before February 2018 (Kissei pipeline, February 2018)
  • 07 Feb 2018 Bedoradrine is available for licensing as of 12 Feb 2018. www.medicinova.com
  • 08 Jun 2016 Phase-I development is ongoing for Chronic obstructive pulmonary disease in USA (Kissei Pharmaceutical pipeline, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top